Triazolam

Ultra-short duration of action with a half-life of 1.5 to 5.5 hours distinguishes triazolam, a Schedule IV triazolobenzodiazepine used for short-term treatment of insomnia. Laboratory testing applications include forensic toxicology investigations, postmortem toxicology, driving under the influence of drugs (DUID) cases, drugs of abuse screening, and clinical toxicology assessments. UTAK’s Benzodiazepines Plus panels contain triazolam in lyophilized urine and whole blood matrices at multiple concentration levels, supporting both immunoassay screening and confirmation methods used in clinical and forensic laboratories. Stock and custom QC solutions can incorporate related benzodiazepines such as alprazolam, midazolam, clonazepam, lorazepam, temazepam, diazepam, and other commonly monitored sedative-hypnotics to address your laboratory’s comprehensive benzodiazepine and drugs of abuse testing requirements.